Back Login to subscribe 🔔 Set Alert

AVBP ArriVent BioPharma, Inc. Common Stock

15 min delay

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	Truist Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $45	87.58%
	Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $43	65.49%
	ArriVent Biopharma Launches $250M At-The-Market Common Stock Offering Through Jefferies	95.35%
	ArriVent BioPharma Q1 EPS $(0.96) Misses $(0.86) Estimate	87.28%
	ArriVent BioPharma Receives IND Application Clearance From FDA For ARR-002 Treatment For Ovarian And Endometrial Cancers	68.96%